Prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity

Analyze the value of pneumoproteins, immunological parameters, everolimus exposure, pulmonary function tests, distinct radiological patterns, baseline patient characteristics and the development of skin toxicity or mucositis for the prediction of the development and severity of everolimus-induced interstitial lung disease.